Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) Research & Development (2018 - 2025)

AVITA Medical (RCEL) has disclosed Research & Development for 7 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 17.34% year-over-year to $5.7 million, compared with a TTM value of $20.8 million through Dec 2025, up 2.36%, and an annual FY2025 reading of $20.8 million, up 2.35% over the prior year.
  • Research & Development was $5.7 million for Q4 2025 at AVITA Medical, up from $3.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $6.8 million in Q4 2023 and bottomed at $3.1 million in Q2 2022.
  • Average Research & Development over 4 years is $4.8 million, with a median of $4.9 million recorded in 2024.
  • The sharpest move saw Research & Development surged 65.94% in 2023, then crashed 30.95% in 2025.
  • Year by year, Research & Development stood at $3.8 million in 2022, then skyrocketed by 78.07% to $6.8 million in 2023, then decreased by 28.31% to $4.8 million in 2024, then grew by 17.34% to $5.7 million in 2025.
  • Business Quant data shows Research & Development for RCEL at $5.7 million in Q4 2025, $3.7 million in Q3 2025, and $5.1 million in Q2 2025.